The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase.
Discovery efforts were focused on identifying a non-nucleoside antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA polymerase inhibition and in vitro antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides.
Tanis
Steven P
SP
Global Research and Development, Pfizer Inc., San Diego, CA 92121, USA. sptanis@sbcglobal.net
Strohbach
Joseph W
JW
Parker
Timothy T
TT
Moon
Malcom W
MW
Thaisrivongs
Suvit
S
Perrault
William R
WR
Hopkins
Todd A
TA
Knechtel
Mary L
ML
Oien
Nancee L
NL
Wieber
Janet L
JL
Stephanski
Kevin J
KJ
Wathen
Michael W
MW
D000998:Antiviral Agents / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D011480:Protease Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D011810:Quinoxalines / Q000737:chemistry* / Q000494:pharmacology; D012697:Serine Endopeptidases / Q000187:drug effects*
D000998:Antiviral Agents; D011480:Protease Inhibitors; D011810:Quinoxalines; D012697:Serine Endopeptidases; C071910:assemblin